RGD Reference Report - Preventing phosphorylation of dystroglycan ameliorates the dystrophic phenotype in mdx mouse. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Preventing phosphorylation of dystroglycan ameliorates the dystrophic phenotype in mdx mouse.

Authors: Miller, Gaynor  Moore, Chris J  Terry, Rebecca  La Riviere, Tracy  Mitchell, Andrew  Piggott, Robert  Dear, T Neil  Wells, Dominic J  Winder, Steve J 
Citation: Miller G, etal., Hum Mol Genet. 2012 Oct 15;21(20):4508-20. Epub 2012 Jul 18.
RGD ID: 12880014
Pubmed: PMID:22810924   (View Abstract at PubMed)
PMCID: PMC5886373   (View Article at PubMed Central)
DOI: DOI:10.1093/hmg/dds293   (Journal Full-text)

Loss of dystrophin protein due to mutations in the DMD gene causes Duchenne muscular dystrophy. Dystrophin loss also leads to the loss of the dystrophin glycoprotein complex (DGC) from the sarcolemma which contributes to the dystrophic phenotype. Tyrosine phosphorylation of dystroglycan has been identified as a possible signal to promote the proteasomal degradation of the DGC. In order to test the role of tyrosine phosphorylation of dystroglycan in the aetiology of DMD, we generated a knock-in mouse with a phenylalanine substitution at a key tyrosine phosphorylation site in dystroglycan, Y890. Dystroglycan knock-in mice (Dag1(Y890F/Y890F)) had no overt phenotype. In order to examine the consequence of blocking dystroglycan phosphorylation on the aetiology of dystrophin-deficient muscular dystrophy, the Y890F mice were crossed with mdx mice an established model of muscular dystrophy. Dag1(Y890F/Y890F)/mdx mice showed a significant improvement in several parameters of muscle pathophysiology associated with muscular dystrophy, including a reduction in centrally nucleated fibres, less Evans blue dye infiltration and lower serum creatine kinase levels. With the exception of dystrophin, other DGC components were restored to the sarcolemma including α-sarcoglycan, α-/ß-dystroglycan and sarcospan. Furthermore, Dag1(Y890F/Y890F)/mdx showed a significant resistance to muscle damage and force loss following repeated eccentric contractions when compared with mdx mice. While the Y890F substitution may prevent dystroglycan from proteasomal degradation, an increase in sarcolemmal plectin appeared to confer protection on Dag1(Y890F/Y890F)/mdx mouse muscle. This new model confirms dystroglycan phosphorylation as an important pathway in the aetiology of DMD and provides novel targets for therapeutic intervention.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
DMDHumanDuchenne muscular dystrophy  ISODmd (Mus musculus) RGD 
DmdRatDuchenne muscular dystrophy  ISODmd (Mus musculus) RGD 
DmdMouseDuchenne muscular dystrophy  IMP  RGD 

Objects Annotated

Genes (Rattus norvegicus)
Dmd  (dystrophin)

Genes (Mus musculus)
Dmd  (dystrophin, muscular dystrophy)

Genes (Homo sapiens)
DMD  (dystrophin)


Additional Information